Comprehensive identification of NRG1 fusions in 25,203 patients with solid tumors

Abstract NRG1 fusion is an emerging oncogenic driver, and the FDA has approved drugs for the treatment of non-small cell lung cancer and pancreatic cancer associated with NRG1 fusions. This study retrospectively analyzed data from 25,203 patients with solid tumors who underwent next-generation seque...

Full description

Saved in:
Bibliographic Details
Main Authors: Shui Xiang, Yiwen Zheng, Mengxiao Wang, Xuewen Liu, Xing Zhang, Dongsheng Chen, Guangxian Meng, Hongtao Xu, Xiaoxuan Wang
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:npj Precision Oncology
Online Access:https://doi.org/10.1038/s41698-025-01044-y
Tags: Add Tag
No Tags, Be the first to tag this record!